SMi’s 4th annual ADC Summit 2015, taking place on the 18th - 19th May 2015, will be held at Holiday Inn Bloomsbury in London, UK.
LONDON, ENGLAND, -
(EINPresswire via NewMediaWire) - March 31, 2015 - -- SMi is delighted to have Angela Romanelli, Senior Director of Biomarkers at ImmunoGen Inc. giving the opening address at the 4th annual ADC Summit 2015 on 18th - 19th May in London, UK. Her talk will focus on how to improve drug development success by linking ADC therapy to the patient and will answer the question: How does tumour biology impact sensitivity to the ADC payload?
She will also discuss how targeting antigen expression is only the starting point and how to build the right biomarker test by highlighting how the right assay on the right sample is critical for enabling selection of the right patient in the clinic.Angela Romanelli's interesting speech on biomarkers will kick-start this year's ADC Summit and open up the floor for attendees and speakers to share, confer and debate on how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.
For the full conference programme and list of expert speakers visit www.drugconjugates.com/EIN
By attending this conference, attendees will be able to network with pharmaceutical and academic experts in the field including: Ablynx, ADC Biotechnology, Antikor Biopharma Ltd., Bicycle Therapeutics Limited, BioPharmaLogic Ltd., Boult Wade Tennant, Clinical Network Services (UK) Ltd, Crescendo Biologics Ltd, Cristal Therapeutics, Endocyte, Inc., ImmunoGen, Imperial College London, Institut de Recherches Internationales Servier, King's College London, NBE-Therapeutics AG, Novasep S A S, Philochem AG, Queens University Belfast, Roche, SafeBridge Europe, Limited, Spirogen, Tagworks Pharmaceuticals, University College London, University of Bern, University of Leeds and more...
Reasons to Attend:
• Hear more about the payload developments
• Receive updates on ADCs in clinical trials
• Learn more about biodistribution and tumour penetrations
• Aim for improvement of the therapeutic index
• Discover strategies for effective targeting ADC off-target toxicities
• Understand the status of the development of novel binding moieties
In addition to the event, there will be an interactive half-day post-conference workshop entitled: ADCs: A Journey Through Development, taking place on the 20th May at the Holiday Inn Bloomsbury in London, UK.
Workshop Leaders: Dr. Richard Turner, Principle Consultant, Natalie Thomas, Consultant, Simon Bishop, Associate Consultant at BioDesk
For those who are interested in attending, there is currently a £100 early bird discount available which will expire on the 31st of March 2015.
For more information or to register for this conference please visit www.drugconjugates.com/EIN
Alternatively contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk
ADC Summit 2015 is proud to be sponsored by: Heraeus Precious Metals & Nanotemper Technologies Ltd
-------------------------- END --------------------------
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Sarah Watson
SMi Group Ltd
+442078276184